Suppr超能文献

系统评价方法学在青光眼成本效用分析中健康状态值的研究。

Systematic methodological review of health state values in glaucoma cost-utility analyses.

机构信息

School of Population and Public Health, University of British Columbia, 2206 E Mall, Vancouver, BC, V6T1Z3, Canada.

Department of Ophthalmology and Visual Sciences, University of Alberta, 400, 10924, 107 Avenue, Edmonton, AB, T5H 0X5, Canada.

出版信息

Eur J Health Econ. 2024 Nov;25(8):1417-1435. doi: 10.1007/s10198-023-01663-x. Epub 2024 Feb 27.

Abstract

IMPORTANCE

Describing the characteristics and sources of health state utility values and reporting practice in the literature of cost-utility analyses facilitates an understanding of the level of the transparency, validity, and generalizability of cost-utility analyses. Improving the quality of reporting will support investigators in describing the incremental value of emerging glaucoma interventions.

OBJECTIVE

To describe the state of practice among published glaucoma cost-utility analysis studies, focusing on valuation of health and the quality of reporting.

EVIDENCE REVIEW

We searched several databases including Medline, CINHAL, Embase, Web of Science, Scopus, Biosis previews, the Health Economic Evaluations Database, and the NHS Economic Evaluation Database (NHS EED). We included full-text, English, published cost-utility analyses of glaucoma interventions with quality-adjusted life years (QALYs) as the primary outcome measure to calculate incremental cost-utility ratios. Excluded studies were non-English language, reviews, editorials, protocols, or other types of economic studies (cost-benefit, cost-minimization, cost-effectiveness). Study characteristics, operational definitions of glaucoma health states and health state utilities were extracted. The original source of the health utility was reviewed to determine the scale of measurement and the source of preference weighting. Items from the Systematic Review of Utilities for Cost-Effectiveness (SpRUCE checklist) were used to assess the reporting and quality of health utilities in glaucoma CUA.

FINDINGS

43 CUAs were included, with 11 unique sources of health utilities. A wide range of health utilities for the same Hodapp-Parrish-Anderson glaucoma health states were reported; ocular hypertension (0.84-0.95), mild (0.68-0.94), moderate (0.57-0.92), advanced (0.58-0.88), severe/blind (0.46-0.76), and bilateral blindness (0.26-0.5). Most studies reported the basis for using health utilities (34, 79%) and any assumptions or adjustments applied to the health utilities (22, 51%). Few studies reported a framework for assessing the relevance of health utilities to a decision context (8, 19%). Even fewer (3, 7%) applied a systematic search strategy to identify health utilities and used a structured assessment of quality for inclusion. Overall, reporting has not improved over time.

CONCLUSIONS AND RELEVANCE

This review describes that few CUAs describe important rationale for using health state utility values. Including additional details on the search, appraisal, selection, and inclusion process of health utility values improves transparency, generalizability and supports the assessment of the validity of study conclusions. Future investigations should aim to use health utilities on the same scale of measurement across health states and consider the source and relevance to the decision context/purpose of conducting that cost-utility study.

摘要

重要性

描述健康状态效用值的特征和来源,并在成本效用分析文献中报告实践,有助于理解成本效用分析的透明度、有效性和可推广性。提高报告质量将有助于研究人员描述新兴青光眼干预措施的增量价值。

目的

描述已发表的青光眼成本效用分析研究中的实践状况,重点是健康评估和报告质量。

证据回顾

我们在多个数据库中进行了搜索,包括 Medline、CINHAL、Embase、Web of Science、Scopus、Biosis previews、Health Economic Evaluations Database 和 NHS Economic Evaluation Database (NHS EED)。我们纳入了全文、英文、发表的青光眼干预措施的成本效用分析,以质量调整生命年 (QALY) 作为主要结局指标来计算增量成本效用比。排除了非英语语言、综述、社论、方案或其他类型的经济研究(成本效益、成本最小化、成本效果)。提取了研究特征、青光眼健康状况和健康状况效用的操作定义。审查了健康效用的原始来源,以确定测量尺度和偏好权重的来源。使用系统评价效用成本效益分析(SpRUCE 清单)中的项目评估青光眼 CUA 中的健康效用报告和质量。

发现

纳入了 43 项 CUAs,有 11 个独特的健康效用来源。报告了同一 Hodapp-Parrish-Anderson 青光眼健康状况的广泛健康效用;眼压升高 (0.84-0.95)、轻度 (0.68-0.94)、中度 (0.57-0.92)、晚期 (0.58-0.88)、严重/失明 (0.46-0.76) 和双侧失明 (0.26-0.5)。大多数研究报告了使用健康效用的依据(34,79%)和对健康效用应用的任何假设或调整(22,51%)。很少有研究报告了评估健康效用与决策背景相关性的框架(8,19%)。更少的(3,7%)应用系统搜索策略来识别健康效用,并使用结构化的质量评估进行纳入。总体而言,报告质量并未随着时间的推移而提高。

结论和相关性

本综述表明,很少有 CUAs 描述了使用健康状态效用值的重要原理。包括有关健康效用值搜索、评估、选择和纳入过程的更多详细信息,可提高透明度、可推广性,并支持对研究结论有效性的评估。未来的研究应旨在在健康状态之间使用相同度量的健康效用,并考虑来源和与决策背景/进行该成本效用研究的目的的相关性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验